Blossom Pharmaceuticals Initiates Class II Recall of Dynashield Skin Protectant Over cGMP Deviations in India
Blossom Pharmaceuticals has initiated a Class II recall of 1,560 units of Dynashield Skin Protectant (Zinc Oxide) due to cGMP deviations at its Bardej, Goa, India facility. This impacts Dynarex Corporation and US nationwide distribution, signaling critical supply chain and regulatory risks for procurement and regulatory affairs teams.
FDA-Initiated Class II Recall of Dynashield Skin Protectant Due to cGMP Failures
Blossom Pharmaceuticals, operating from Bardej, Goa, India, has initiated a Class II voluntary recall, designated D-0202-2026, for its Dynashield Skin Protectant. This product, a human over-the-counter (OTC) drug formulated with Zinc Oxide, is manufactured for Dynarex Corporation and distributed nationwide across the USA. The recall, initiated on October 31, 2025, specifically targets 1560 containers from Lot #: A092334 (Exp. Date 6/26) and Lot #: A092421 (Exp. Date 7/27). The stated reason for this action is significant deviations from current Good Manufacturing Practices (cGMP). For procurement directors, this event mandates an immediate assessment of inventory levels for Zinc Oxide-based topical products and a review of supplier diversification strategies to mitigate reliance on potentially compromised manufacturing sites. Regulatory affairs heads must recognize this as a critical compliance lapse originating from an international facility, highlighting the FDA's robust oversight even for OTC preparations. This incident underscores the imperative for stringent quality assurance protocols throughout the entire supply chain.
Operational Scrutiny: Blossom Pharmaceuticals' Indian Facility and Global Supply Chain Risks
The recall originating from Blossom Pharmaceuticals' facility in Bardej, Goa, India, places a direct spotlight on the operational integrity of this specific manufacturing site and, by extension, the broader challenges within the global pharmaceutical supply chain. While the precise nature of the cGMP deviations remains undisclosed, such issues typically encompass deficiencies in quality control, facility maintenance, equipment calibration, or process validation. For supply chain VPs, this situation exemplifies the inherent vulnerabilities of sourcing active pharmaceutical ingredients (APIs) or finished drug products from single international locations without robust secondary sourcing options. The firm-initiated, voluntary nature of the recall suggests Blossom Pharmaceuticals acknowledged the non-compliance, yet the "Ongoing" status indicates that the FDA has not yet confirmed the adequacy of corrective and preventive actions (CAPA). This ongoing uncertainty necessitates vigilance for business development executives considering partnerships or expanding existing relationships with manufacturers in regions prone to cGMP challenges, as it directly impacts product availability and market access in the United States.
Downstream Impact: Dynarex Corporation's Exposure and US Market Implications
Dynarex Corporation, based in Orangeburg, NY, USA, as the brand owner and marketer of Dynashield Skin Protectant (NDC 67777-407-04), bears the immediate commercial and reputational brunt of this recall. The withdrawal of 1560 containers of this Zinc Oxide product from the nationwide US market represents a tangible disruption to Dynarex's product availability and could lead to temporary market share erosion. Procurement directors at healthcare providers or distributors relying on Dynarex for this specific human OTC drug must swiftly evaluate their stock and explore alternative products or suppliers to ensure continuity of care. The "Made in India" designation on the product packaging underscores the critical importance of comprehensive supplier audits and ongoing quality oversight for all outsourced manufacturing, particularly for products intended for sensitive markets like the USA. Regulatory affairs teams should reinforce the necessity of robust quality agreements with contract manufacturing organizations (CMOs) to clearly define responsibilities and ensure adherence to international cGMP standards, thereby safeguarding against such Class II recall events.
Blossom Pharmaceuticals' Compliance Record and Future Regulatory Outlook
This Class II recall for cGMP deviations represents Blossom Pharmaceuticals' primary documented regulatory event within the available intelligence. While the company is currently assessed with a "low" risk band, this incident will undoubtedly trigger intensified scrutiny from the FDA. For procurement and business development executives, this event serves as a critical data point in their ongoing assessment of supplier reliability and compliance. The absence of a public record detailing prior FDA Warning Letters, Form 483 observations, or Import Alerts suggests that this may be an isolated, albeit serious, lapse in cGMP adherence. However, the "Ongoing" status of the recall signifies that the FDA has not yet concluded its review of Blossom Pharmaceuticals' corrective actions. This situation elevates the probability of future FDA inspections at the Bardej, Goa facility. Any subsequent findings of non-compliance could lead to more severe enforcement actions, including the potential issuance of an Import Alert, which would effectively bar all products from this facility from entering the US market, posing substantial long-term supply chain risks.